Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

Biotechnology

Healthcare
$3.14 -0.26%

-$0.02 today

Market cap
$53.94M
Beta
1.49
P/E (TTM)
-3.5
EPS (TTM)
-$1.67
52W Low $3.28High $9.82

Volume 0.10M

Average 0.08M

VRCA Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Verrica Pharmaceuticals Inc.NASDAQ: VRCA

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables declines year over year

Q1 FY2026 accounts receivables of $2.42M (cash outflow) fell 56.5% year over year, ahead of the -210.4% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at +121.9% a year.

Context

  • Accounts receivables amounted to 15.0% of revenue in FY2025, down 42.4 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -56.5% holds above the trailing-twelve-month pace of -210.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.42M-225.1% QoQ
Last fiscal yearDec 2025
-$5.32M-222.6% YoY
LTMMar 2026
-$2.16M-210.4% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-56.5%——
1 year-222.6%——
3-year CAGR+121.9%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(5.32M) USD
Year-over-year change
-222.6%

Accounts Receivables vs competitors

How VRCA compares with its peers on the latest reported figures

  • VRCA's LTM Mar 2026 accounts receivables of $2.16M is the 2nd largest of the 5 companies compared; the peer median is $0.
  • Its year-over-year change of -210.4% is the highest of 2, against a peer median of -1190.2%.
  • Accounts receivables amounts to 5.8% of revenue for VRCA, versus a peer median of 0.0%.
VRCA Competitors Peer median
Accounts Receivables for VRCA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SABSSAB Biotherapeutics, Inc.LTM Jun 2026$2.45M -1190.2%——
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026$2.16M -210.4%+121.9%5.8%
QTTBQ32 Bio Inc.LTM Mar 2026$0 ——0.0%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$0 ———
BOLDBoundless Bio, Inc.LTM Mar 2026$0 ———
Peer median (excluding VRCA) $0-1190.2%—0.0%

Competitors are the stored peer set for VRCA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(35.08M)(24.49M)(67M)(76.58M)(17.89M)
Depreciation & Amortization472K718K836K1.27M429K
Deferred Income Tax66K0000
Stock-Based Compensation6.05M4.99M14.38M7.16M3.32M
Change in Working Capital(535K)(1.8M)9.86M2.03M(6.25M)
Accounts Receivables0(487K)(3.93M)4.34M(5.32M)
Inventory0487K000
Accounts Payables497K(338K)2.2M(568K)176K
Other Working Capital(1.03M)(1.46M)11.59M(1.74M)(1.11M)
Other Non-Cash Items1.44M1.93M3.35M5.19M2.76M
Operating Cash Flow(27.58M)(18.65M)(38.58M)(60.93M)(17.63M)
Capital Expenditures(883K)(302K)(362K)(27K)0
Acquisitions (Net)00000
Purchases of Investments(68.91M)(4.49M)000
Sales of Investments69M59.01M000
Other Investing Activities(201K)(180K)08K0
Investing Cash Flow(998K)54.04M(362K)(19K)0
Debt Repayment4.97M(43.75M)44.08M(2.06M)(48.2M)
Common Stock Issued28.12M26.9M30.3M39.64M50.07M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities558K(17K)(169K)155K(420K)
Financing Cash Flow33.65M(16.87M)74.21M37.73M1.45M
Effect of Forex Changes00000
Net Change in Cash5.07M18.52M35.27M(23.22M)(16.18M)
Free Cash Flow(28.47M)(18.95M)(38.94M)(60.95M)(17.63M)

Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

Intrinsic Alpha fair value

Locked

Current Price

$3.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.